Drug Profile
Research programme: cancer and infectious disease therapeutics - PMV Pharmaceuticals/Chiromics
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Chiromics; PMV Pharmaceuticals
- Class Small molecules
- Mechanism of Action Tumour suppressor protein p53 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Viral infections
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Cancer in USA
- 18 Jun 2019 Early research is still ongoing for cancer in USA (PMV Pharma pipeline, June 2019)
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA